Evonik invests US$220 million in partnership with the U.S. Government to build new lipid production facility for mRNA-based therapies in the U.S.
Important contribution to the development of new mRNA therapies beyond COVID-19 vaccines
03-Jun-2022 -
Evonik is building a new, highly flexible, global-scale production facility for pharmaceutical lipids in the United States. The new plant at Evonik’s Tippecanoe site in Lafayette, Indiana, will broadly position the Group for future growth in novel mRNA-based therapies beyond COVID-19 vaccines and ...
Evonik
investments
lipids
+1